Viatris Inc. (NASDAQ:VTRS) and Opus Genetics, Inc. (NASDAQ:IRD) revealed topline results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for ...
A new eye drop, Vizz, was recently FDA approved and is helping people regain near vision without glasses. Originally used for glaucoma, the drops are now repurposed for presbyopia (age-related ...
The Print on MSNOpinion
Why fixing near vision clears a surprisingly high bar for public investment
Near-vision loss quietly erodes productivity and income for millions of working adults at the last mile, yet fixing it is ...
The FDA has approved a first-of-its-kind eye drop that addresses a common vision condition. The once-daily drops will treat an age-related condition that causes blurry near vision. The drops are ...
With regards to near vision, rates of unaddressed near vision impairment are estimated to be greater than 80% in western, eastern and central sub-Saharan Africa, while comparative rates in high-income ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback